Hugo Fry becomes head of Zentiva's office in Russia
This article was originally published in Scrip
Zentiva, part of Sanofi–Aventis, has appointed Hugo Fry head of its representative office in Moscow, Russia. He succeeded Grigory Chudakov. Most recently, Mr Fry was director of oncology, diabetes and cardio-hospital departments at Sanofi–Aventis's Russian subsidiary where he had also served as marketing director.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.